BMS986165

Unassigned

New Medicines

Moderate-to-severe plaque psoriasis

Information

New molecular entity
Bristol-Myers Squibb
Bristol-Myers Squibb

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

TYK2 inhibitor. Tyrosine kinase 2 (TYK2) is a member of the Janus kinase (JAK) family.
Prevalence of psoriasis is estimated to be about 1.3-2.2% in the UK, with the highest prevalence being in white people. Men and women are equally affected. It can occur at any age but the majority of cases first present before the age of 35 years. It is uncommon in children. Plaque psoriasis accounts for 90% of all people with psoriasis [1].
Moderate-to-severe plaque psoriasis
Oral